☆ 4.6 Review

Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial

Mika Mizuno et al.

Summary: The phase 3 VELIA trial evaluated the efficacy of veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade serous ovarian carcinoma. In the subgroup of Japanese patients, the veliparib-throughout arm showed numerically longer median progression-free survival compared to the control arm. Pharmacokinetics were similar between Japanese and non-Japanese patients. Further investigation is needed to validate these results.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Homologous Recombination Deficiencies and Hereditary Tumors

Hideki Yamamoto et al.

Summary: Homologous recombination (HR) is a crucial process for repairing DNA double-strand breaks and is associated with inherited susceptibility to specific types of cancers. Variants in different genes within the HR pathway have varying effects, but the protein products of these genes are essential for maintaining a high-fidelity DNA repair system by HR.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Homologous Recombination Deficiency: Concepts, Definitions, and Assays

Mark D. Stewart et al.

Summary: Homologous recombination deficiency (HRD) is a tumor phenotype characterized by the inability of cells to repair DNA double-strand breaks effectively. Research has identified opportunities to improve the consistency in defining HRD and measuring homologous repair status parameters, benefiting the broader cancer community.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China

Jing Ni et al.

Summary: This is the first real-world study of HRD status in ovarian cancer patients in China, and we demonstrate that HRD is an independent predictive biomarker for PARP inhibitors treatment in Chinese ovarian cancer patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors

Lola Paulet et al.

Summary: DNA double-strand breaks are critical DNA damages for cells, and some cancers with homologous recombination deficiency (HRD) exhibit increased sensitivity to PARP inhibitors (PARPi). A major challenge is the development of tests capable of detecting HRD phenotype and predicting sensitivity to PARPi.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk et al.

Summary: This study evaluates the efficacy of rucaparib as a first-line maintenance treatment in ovarian cancer patients, showing significant benefits of rucaparib compared to placebo in patients with and without HRD.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Obstetrics & Gynecology

Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)

Ning Li et al.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Pathology

Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort Validation of Decentralized Genomic Profiling

Carsten Denkert et al.

Summary: The diagnostic evaluation of homologous recombination deficiency (HRD) is crucial for targeted therapy strategies in ovarian carcinoma patients. Through next-generation sequencing, we found that 38.1% of the 514 ovarian carcinoma samples were HRD positive, with significant associations with high-grade serous histology, grade 3 tumors, and age <60 years. The concordance between two laboratories was 96.9%, with a sensitivity of 94.6% and a specificity of 98.4%. The proportion of HRD-positive tumors in our real-life cohort was consistent with the recent clinical trial results.

JOURNAL OF MOLECULAR DIAGNOSTICS (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?

N. Y. L. Ngoi et al.

Summary: The recognition of homologous recombination deficiency in high-grade serous ovarian cancer has led to the development of PARP inhibitors as an important therapy. However, controversies exist around defining and evaluating HRD, and the dynamic nature of tumoral HRD status poses challenges. It is critical to optimize HRD testing to maximize the potential benefits of PARP inhibitors for patients with HGSOC.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial

Keiichi Fujiwara et al.

Summary: In the Japan subset of the PAOLA-1 trial, the addition of maintenance olaparib to bevacizumab showed a significant PFS benefit in patients with newly diagnosed, advanced ovarian cancer. Adverse events in the Japan subset were similar to those in the overall population, supporting the conclusion of the PAOLA-1 trial.

JOURNAL OF GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

Kyung Jin Eoh et al.

BMC CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

M. E. Robson et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

R. L. Coleman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

I. Ray-Coquard et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

Euan A. Stronach et al.

MOLECULAR CANCER RESEARCH (2018)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

K. Moore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Oncology

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

A. Karam et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

Hui Zhang et al.

CELL (2016)

Add to Collection

Article Oncology

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting the DNA Damage Response in Cancer

Mark J. O'Connor

MOLECULAR CELL (2015)

Add to Collection

Article Oncology

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

V. Abkevich et al.

BRITISH JOURNAL OF CANCER (2012)

Add to Collection

Article Oncology

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

Tatiana Popova et al.

CANCER RESEARCH (2012)

Add to Collection

Article Oncology

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

Nicolai J. Birkbak et al.

CANCER DISCOVERY (2012)

Add to Collection

Article Multidisciplinary Sciences

Integrated genomic analyses of ovarian carcinoma

D. Bell et al.

NATURE (2011)

Add to Collection

Article Medicine, General & Internal

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy J. Perren et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Review Oncology

DNA repair pathways as targets for cancer therapy

Thomas Helleday et al.

NATURE REVIEWS CANCER (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.